DE2840442C2 - Use of the diketopiperazine L-Leu-L-Trp as a flavoring for beverages with a bitter taste - Google Patents
Use of the diketopiperazine L-Leu-L-Trp as a flavoring for beverages with a bitter tasteInfo
- Publication number
- DE2840442C2 DE2840442C2 DE2840442A DE2840442A DE2840442C2 DE 2840442 C2 DE2840442 C2 DE 2840442C2 DE 2840442 A DE2840442 A DE 2840442A DE 2840442 A DE2840442 A DE 2840442A DE 2840442 C2 DE2840442 C2 DE 2840442C2
- Authority
- DE
- Germany
- Prior art keywords
- diketopiperazine
- leu
- trp
- bitter
- beverages
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- BXRNXXXXHLBUKK-UHFFFAOYSA-N piperazine-2,5-dione Chemical compound O=C1CNC(=O)CN1 BXRNXXXXHLBUKK-UHFFFAOYSA-N 0.000 title claims description 24
- 235000019658 bitter taste Nutrition 0.000 title claims description 7
- BQVUABVGYYSDCJ-ZFWWWQNUSA-N Leu-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](N)CC(C)C)C(O)=O)=CNC2=C1 BQVUABVGYYSDCJ-ZFWWWQNUSA-N 0.000 title description 8
- 235000013361 beverage Nutrition 0.000 title description 5
- 239000000126 substance Substances 0.000 claims description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 5
- 239000003765 sweetening agent Substances 0.000 claims description 5
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 235000003599 food sweetener Nutrition 0.000 claims description 3
- 235000019454 L-leucine Nutrition 0.000 claims description 2
- 239000004395 L-leucine Substances 0.000 claims description 2
- 239000007859 condensation product Substances 0.000 claims description 2
- 235000021551 crystal sugar Nutrition 0.000 claims description 2
- 229960003136 leucine Drugs 0.000 claims description 2
- 235000021092 sugar substitutes Nutrition 0.000 claims description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 2
- 239000000654 additive Substances 0.000 claims 1
- 239000003086 colorant Substances 0.000 claims 1
- 229960004799 tryptophan Drugs 0.000 claims 1
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 22
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
- 235000001258 Cinchona calisaya Nutrition 0.000 description 11
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 11
- 229960000948 quinine Drugs 0.000 description 11
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 235000000346 sugar Nutrition 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 239000011248 coating agent Substances 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 235000015122 lemonade Nutrition 0.000 description 5
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 4
- BQVUABVGYYSDCJ-UHFFFAOYSA-N Nalpha-L-Leucyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)C(N)CC(C)C)C(O)=O)=CNC2=C1 BQVUABVGYYSDCJ-UHFFFAOYSA-N 0.000 description 4
- 235000021552 granulated sugar Nutrition 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- KHSCYOFDKADJDJ-NQLMQOPMSA-N Cynaropicrin Chemical compound OCC(=C)C(=O)O[C@H]1CC(=C)[C@@H]2C[C@H](O)C(=C)[C@@H]2[C@H]2OC(=O)C(=C)[C@H]12 KHSCYOFDKADJDJ-NQLMQOPMSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- STQKFHDZSADKCG-UHFFFAOYSA-N cynaropicrin Natural products OC1CC2C(C3OC(=O)C(=C)C3C(CC2=C)OC(=O)C(=C)O)C1=C STQKFHDZSADKCG-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 235000002639 sodium chloride Nutrition 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 244000019459 Cynara cardunculus Species 0.000 description 2
- 235000019106 Cynara scolymus Nutrition 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 235000016520 artichoke thistle Nutrition 0.000 description 2
- 235000013405 beer Nutrition 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000000686 essence Substances 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 239000001096 (4-ethenyl-1-azabicyclo[2.2.2]octan-7-yl)-(6-methoxyquinolin-4-yl)methanol hydrochloride Substances 0.000 description 1
- LBSFSRMTJJPTCW-DSXUQNDKSA-N (r)-[(2s,4s,5r)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol;hydrochloride Chemical compound Cl.C([C@H]([C@H](C1)C=C)C2)CN1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LBSFSRMTJJPTCW-DSXUQNDKSA-N 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- QDHHCQZDFGDHMP-UHFFFAOYSA-N Chloramine Chemical compound ClN QDHHCQZDFGDHMP-UHFFFAOYSA-N 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 235000008694 Humulus lupulus Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- NFVNYBJCJGKVQK-ZDUSSCGKSA-N N-[(Tert-butoxy)carbonyl]-L-tryptophan Chemical compound C1=CC=C2C(C[C@H](NC(=O)OC(C)(C)C)C(O)=O)=CNC2=C1 NFVNYBJCJGKVQK-ZDUSSCGKSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- LYMVXFSTACVOLP-ZFWWWQNUSA-N Trp-Leu Chemical compound C1=CC=C2C(C[C@H]([NH3+])C(=O)N[C@@H](CC(C)C)C([O-])=O)=CNC2=C1 LYMVXFSTACVOLP-ZFWWWQNUSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- -1 colorings Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 229940109275 cyclamate Drugs 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 231100000895 deafness Toxicity 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 235000020094 liqueur Nutrition 0.000 description 1
- 235000014666 liquid concentrate Nutrition 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000019520 non-alcoholic beverage Nutrition 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 description 1
- IFGCUJZIWBUILZ-UHFFFAOYSA-N sodium 2-[[2-[[hydroxy-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyphosphoryl]amino]-4-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoic acid Chemical compound [Na+].C=1NC2=CC=CC=C2C=1CC(C(O)=O)NC(=O)C(CC(C)C)NP(O)(=O)OC1OC(C)C(O)C(O)C1O IFGCUJZIWBUILZ-UHFFFAOYSA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- HXJUTPCZVOIRIF-UHFFFAOYSA-N sulfolane Chemical compound O=S1(=O)CCCC1 HXJUTPCZVOIRIF-UHFFFAOYSA-N 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 108010080629 tryptophan-leucine Proteins 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
- A23L2/52—Adding ingredients
- A23L2/56—Flavouring or bittering agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
- A23L27/20—Synthetic spices, flavouring agents or condiments
- A23L27/201—Compounds of unspecified constitution characterised by the chemical reaction for their preparation
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
- A23L27/20—Synthetic spices, flavouring agents or condiments
- A23L27/205—Heterocyclic compounds
- A23L27/2054—Heterocyclic compounds having nitrogen as the only hetero atom
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Description
Die Erfindung betrifft die Verwendung des Diketopiperazins, das das Kondensationsprodukt von L-Leucin und L-Tryptophan darstellt, als Geschmacksstoff für Getränke mit bitterer Geschmacksrichtung.The invention relates to the use of diketopiperazine, which is the condensation product of L-leucine and L-tryptophan, as a flavoring for beverages with a bitter taste.
Es ist bekannt, zur Herstellung von Getränken bitterer Geschmacksrichtung Bitterstoffe aus Pflanzen zu verwenden. Neben den Hopfenbestandteilen, die im Bier enthalten sind, sowie Extrakten aus Artischocken, dient vor allem Chinin zur Erzeugung des bitteren Geschmacks \'on Getränken, beispielsweise von bitteren Limonaden. Chinin wird seit alters her zur Behandlung der Malaria angewendet; es verursacht jedoch schon in relativ geringen Dosen Nebenwirkungen wie Schwindel, Kopfschmerz, Herzbeschwerden. Der Ersatz des Chinins durch physiologisch unbedenkliche Bitterstoffe wäre daher erwünscht.It is known to use bitter substances from plants for the production of beverages with a bitter taste to use. In addition to the hops contained in beer and extracts from artichokes, quinine is mainly used to create the bitter taste of beverages, for example bitter ones Sodas. Quinine has been used to treat malaria since ancient times; it causes however, even in relatively small doses, side effects such as dizziness, headache, heart problems. The replacement of quinine with physiologically harmless bitter substances would therefore be desirable.
In der DE-OS 26 54 184 wird vorgeschlagen, einen Inhaltsstoff der Artischocke, das »Cynaropicrin«, als dem Chinin überlegenen Bitterstoff zu verwenden. Cynaropicrin ist zwar dem Chinin gegenüber etwas stärker bitter, zeigt aber eine deutlich höhere akute Toxizität.In DE-OS 26 54 184 it is proposed that an ingredient of the artichoke, the "cynaropicrin", as to use bitter substance superior to quinine. Cynaropicrine is something compared to quinine more bitter, but shows a significantly higher acute toxicity.
Es wurde nun gefunden, daß das DiketopiperazinIt has now been found that the diketopiperazine
L-Leu-L-TrpL-Leu-L-Trp
besonders vorteilhaft zur Herstellung von Getränken bitterer Geschmacksrichtung verwendet werden kann. Zwar liegt der Bitterschwellenwert etwas höher als der von Chinin und Cynaropicrin, jedoch ist die Toxizität der Diketopiperazine erheblich geringer, so daß sich bei ihrer Verwendung eine breitere Sicherheitsmarge ergibt. Von Vorteil ist ferner, daß die Diketopiperazine aufgrund ihrer großen chemischen Stabilität im Körper nicht metabolisiert, sondern unverändert über den Urin ausgeschieden werden und somit den Organismus nicht unnötig belasten.can be used particularly advantageously for the production of beverages with a bitter taste. Although the bitter threshold is slightly higher than that of quinine and cynaropicrine, the toxicity is less the diketopiperazines are considerably lower, so that there is a broader safety margin when they are used results. It is also advantageous that the diketopiperazines because of their great chemical stability in the body not metabolized, but excreted unchanged in the urine and thus not the organism burden unnecessarily.
Die große chemische Stabilität des Diketopiperazins wirkt sich auch insofern günstig aus. als es in den Getränken bei Raumtemperatur unbeschränkt haltbar sind. Hinsichtlich der Haltbarkeit besteht gegenüber Cynaropicrin e:in deutlicher Vorteil. Während Cynaropicrin nach dreistündigem Kochen in entminderalisiertem Wasser deutliche Zersetzungserscheinungen zeigt, sind das Diketopiperazin nicht nur unter diesen Bedingungen, sondern auch nach dreistündigem Kochen in 0,5prozentiger Zitronensäure (pH 2,4) unverändert. Getränke mit dem Diketopiperazin als Bitterstoff und auch Konzentrate zeichnen sich dementsprechend nicht nur durch hervorragende Lagerfähigkeit aus, sie können auch unbedenklich der Hitzesterilisierung unterworfen werden.The great chemical stability of diketopiperazine also has a beneficial effect in this respect. than it in the Drinks can be kept indefinitely at room temperature. In terms of durability, there is an opposite Cynaropicrin e: in clear advantage. While cynaropicrin after three hours of cooking in demineralized Water shows clear signs of decomposition, the diketopiperazines are not only available under these conditions, but also unchanged after three hours of boiling in 0.5 percent citric acid (pH 2.4). Accordingly, drinks with diketopiperazine as a bitter substance and concentrates do not stand out only characterized by their excellent shelf life; they can also be safely subjected to heat sterilization will.
Ein weiterer Vorteil des Diketopiperazins gegenüber den bisher beschriebenen, aus Pflanzen gewonnenen Bitterstoffen besteht darin, daß sie leicht in höchster Reinheit und gleichbleibender Qualität vollsynthetisch hergestellt werden können.Another advantage of diketopiperazine over the previously described ones obtained from plants Bitter substances consists in the fact that they are easily fully synthetic in the highest purity and consistent quality can be produced.
Dazu dienen übliche Verfahren.The usual procedures are used for this.
Zur Herstellung eines alkoholfreien bitteren Getränks kann das Diketopiperazin als Feststoff oder als flüssiges Konzentrat zugesetzt werden. Wird es als Festsubstanz eingesetzt, fällt häufig (in Abhängigkeit von Struktur und Korngröße) die langsame Lösegeschwindigkeit auf. Diese Eigenschaft läßt sich durch einen Mahlprozeß zurückdrängen; als besonders vorteilhaft hat sich aber überraschenderweise folgendes Vorgehen herausgestellt Das Diketopiperazin wird in einem geeigneten organischen Solvens gelöst und auf einen festen Träger aufgebracht. ErfindungsgemSß wird z. B. der für die Limonadenherstellung vorgesehene Kristallzucker in einem Dragierkessel mit der gesättigten alkoholischen Diketopiperazinlösung, die zusätzlich einen Kristallisationsverzögerer enthalten kann, besprüht und das Solvens gleichzeitig verdampft Du-Kristallzucker ist nun mit einer dünnen Schicht des Diketopiperazins überzogen. Beim Auflösen dieses Zuckers in Wasser löst sich das Diketopiperazin durch die feine Verteilung genauso schnell wie der Zucker selbst. Anstelle von Kristallzucker lassen sich auch Zuckeraustauschstoffe wie beispielsweise Sorbit, Mannit oder Fructose einsetzen oder auch Süßstoffe wie z. B. Cyclamat. Auf den Träger kennen auch andere zusätzliche Bitterstoffe aufgezogen werden.For making a non-alcoholic bitter drink the diketopiperazine can be added as a solid or as a liquid concentrate. It will be called If solids are used, the slow rate of dissolution often falls (depending on the structure and grain size) on. This property can be suppressed by a grinding process; as particularly advantageous but the following procedure has surprisingly been found: The diketopiperazine is in dissolved in a suitable organic solvent and applied to a solid support. According to the invention z. B. the crystal sugar intended for lemonade production in a coating pan with the saturated alcoholic diketopiperazine solution, which may also contain a crystallization retarder, sprayed and the solvent evaporates at the same time. You-granulated sugar is now covered with a thin layer of the Diketopiperazine coated. When this sugar is dissolved in water, the diketopiperazine dissolves the fine distribution just as quickly as the sugar itself. Instead of granulated sugar can also Use sugar substitutes such as sorbitol, mannitol or fructose or sweeteners such as. B. Cyclamate. Other additional bitter substances can also be absorbed on the carrier.
Für die Herstellung einer Limonade mit Bittergeschmack kann der mit Bitterstoff überzogene Träger als solcher oder auch ein daraus hergestellter Sirup eingesetzt werden. Die erfindungsgemäß hergestellten Getränke können z. B. ferner enthalten: Physiologisch verträgliche Säuren, Essenzen, Aromastoffe, Bitterstoffe, Süßstoffe, Farbstoffe, Kochsalz.For the production of a lemonade with a bitter taste, the carrier coated with bitter substance can be used as such a syrup or a syrup made therefrom can be used. The manufactured according to the invention Drinks can e.g. B. also contain: Physiologically compatible acids, essences, aromatic substances, bitter substances, Sweeteners, colorings, table salt.
Neben der Herstellung von alkoholfreien Getränken kann das Diketopiperazin aber auch für die Herstellung von alkoholischen Getränken wie Bitter-ßranntweinen, Bitter-Likören, Vermuth-Arten, Aperitif-Getränken und Bier verwendet werden. In diesen Fällen können auch vorteilhaft ethanolische Lösungen des Diketopiperazins zur Herstellung eingesetzt werden.In addition to the production of non-alcoholic beverages, the diketopiperazine can also be used for the production of alcoholic beverages such as bitter vintages, bitter liqueurs, Vermuth types, aperitif drinks and Beer can be used. In these cases, ethanolic solutions of diketopiperazine can also be advantageous are used for production.
Herstellung des Diketopiperazins L-Leu-L-TrpProduction of the diketopiperazine L-Leu-L-Trp
(Bei den im folgenden genannten Aminosäuren und ihren Derivaten handelt es sich jeweils um die L-Form.) 456 g Boc-Trp-OH (1,5 Mol) und 151 g N-Methylmor-(The amino acids and their derivatives mentioned below are each in the L-form.) 456 g of Boc-Trp-OH (1.5 mol) and 151 g of N-Methylmor-
pholin (1,5 Mol) werden in 4 1 Dimethylformamid (DMF) gelöst, auf - 15°C abgekühlt und mit 191 g Chloramei-pholine (1.5 mol) are dissolved in 4 l of dimethylformamide (DMF), cooled to - 15 ° C and treated with 191 g of chloramine
bo sensäureisobutylester (1,4 Mol) versetzt. Nach 15 Minuten wird die auf —!5°C gekühlte Lösung von 235 g H-LeU-OCH3 · HCl (1,3 Mol) und 131 g N-Methylmorpholin in 1 1 DMF zugegeben. Man rührt eine Stunde bei 0°C und über Nacht bei Raumtemperatur. Vonisobutyl acid ester (1.4 mol) was added. After 15 minutes, the solution, cooled to -5 ° C., of 235 g of H-LeU-OCH 3 · HCl (1.3 mol) and 131 g of N-methylmorpholine in 1 1 of DMF is added. The mixture is stirred for one hour at 0 ° C. and overnight at room temperature. from
b5 ausgefallenem Salz wird abfiltriert, das Filtrat im Hochvakuum vom DMF befreit, wöbe· ein öl erhalten wird. Beim Aufnehmen des Öls in Essigester wird erneut Salz abgeschieden, das abgetrennt wird. Die erhalteneb5 precipitated salt is filtered off, the filtrate in Freed from DMF in a high vacuum, an oil would be obtained will. When the oil is absorbed in ethyl acetate, salt is again deposited, which is then separated off. The received
Lösung wird bei 00C je 3mal mit 1 N-Natronlauge, Wasser und je 3mal abwechselnd mit ges. KSO4-Lösung und Wasser ausgeschüttelt Die organische Phase wird über MgSO4 getrocknet und eingeengt, wobei 377 g Boc-Trp-Leu-OCH3 (=67% d.Th.) als öl erhalten werden.Solution is at 0 0 C 3 times with 1 N sodium hydroxide solution, water and 3 times alternately with sat. KSO 4 solution and water are extracted by shaking. The organic phase is dried over MgSO 4 and concentrated, 377 g of Boc-Trp-Leu-OCH 3 (= 67% of theory) being obtained as an oil.
377 g Boc-Trp-Leu-OCH3 (0,88 MoI) werden mit 3 1 1 N-HCl in Eisessig Übergossen und eine Stunde bei Raumtemperatur gerührt Die HCl-Eisessig-Mischung wird unter vermindertem Druck abdestilliert und der Rückstand je 3mal mit Ether und Aceton nachgedampft. Nach Aufnehmen des Rückstands in Essigester wird bei 00C je 3mal mit NaHCO3-Lösung und Wasser gewaschen, über MgSO4 getrocknet und eingeengt So werden 255 g H-Trp-Leu-OCHj (=88% d.Th.) als Öl erhalten.377 g of Boc-Trp-Leu-OCH 3 (0.88 mol) are poured with 3 l 1 N-HCl in glacial acetic acid and stirred for one hour at room temperature. The HCl-glacial acetic acid mixture is distilled off under reduced pressure and the residue is mixed 3 times Evaporated ether and acetone. After taking up the residue in Essigester is washed at 0 0 C, 3 times each with NaHCO 3 solution and water, dried over MgSO 4 and concentrated Thus, 255 g of H-Trp-Leu-OCHj (= 88% of theory) as an oil obtain.
255 g H-Trp-Leu-OCH3 (0,77 Mol) wenden mit 2,5 1 Toluol und 320 ml Sulfolan versetzt, 14 Stunden am Rückfluß gekocht und abgekühlt Die abgeschiedenen Kristalle werden abgesaugt, nacheinander mit Toluol, Aceton, Wasser und Aceton gewaschen und getrocknet. Es wird aus Ethanol umkristaliisiert255 g of H-Trp-Leu-OCH 3 (0.77 mol) are mixed with 2.5 1 of toluene and 320 ml of sulfolane, refluxed for 14 hours and cooled Acetone washed and dried. It is recrystallized from ethanol
Ausbeute 164 g Trp-Leu = Leu-Trp (a 71 % d.Th.)Yield 164 g of Trp-Leu = Leu-Trp (a 71% of theory)
Fp.265-266°C.Mp 265-266 ° C.
Elementaranalyse:
berechnet C 68,20
gefunden C 68,60Elemental analysis:
calculated C 68.20
found C, 68.60
H 7,07 H 7,14H 7.07 H 7.14
N 14,04% N 13,65%N 14.04% N 13.65%
Beispiele für das Überziehen von Kristallzucker mit dem Diketopiperazin Leu-TrpExamples of coating granulated sugar with the diketopiperazine Leu-Trp
Beispiel 1 Überziehen ohne KristallisationsverzögererExample 1 Coating without a crystallization retarder
1000 g Kristallzucker der Korngrößenverteilung 0,5-2 mm werden in einem Dragierkessel bei 40° Neigung und einer Drehgeschwindigkeit von 40 UpM bei schwacher Trockenluft von 35° C mit einer Lösung von1000 g of granulated sugar with a grain size distribution of 0.5-2 mm are placed in a coating pan at 40 ° Inclination and a rotation speed of 40 rpm with weak dry air of 35 ° C with a solution from
7 g Leu-Trp7 g Leu-Trp
in 200 ml Methanol über 30 Minuten besprüht. Der mit Diketopiperazin beladene Zucker unterscheidet sich in seinen Rieseleigenschaften nicht vom Ausgangs-Zucker.sprayed in 200 ml of methanol over 30 minutes. The sugar loaded with diketopiperazine differs in its flow properties not from the initial sugar.
Überziehen unter Zusatz von Kristallisationsverzögerer Coating with the addition of a crystallization retarder
Es wird wie in Beispiel 1 verfahren, mit dem Unterschied, daß der methanolischen Diketopiperazin-Lösung 30 g handelsübliches Polyvinylpyrrolidon zugesetzt werden. Auch der so erhaltene Zucker isi in seiner Rieselfähigkeit nicht beeinträchtigt.The procedure is as in Example 1, with the difference that the methanolic diketopiperazine solution 30 g of commercially available polyvinylpyrrolidone are added. The sugar obtained in this way is also in his Flowability not impaired.
Beispiel für die Herstellung einer BitterlimonadeExample of the production of a bitter lemonade
Grundstoff:Basic material:
1,0 kg handelsübliche Zitronenessenz (1 %)
1,0 kg wä ßrige Zitronensäurelösung (50%)
1,0 kg wäßrige Weinsäurelösung (50%)
0,3 kg wäßrige Milchsäurelösung (50%)
1,7 kg Wasser1.0 kg commercial lemon essence (1%)
1.0 kg aqueous citric acid solution (50%)
1.0 kg aqueous tartaric acid solution (50%)
0.3 kg aqueous lactic acid solution (50%)
1.7 kg of water
ίο 5 kg dieses Grundstoffs werden mit 95 kg 60%iger Zuckerlösung, dieίο 5 kg of this raw material become 60% with 95 kg Sugar solution that
0,45 % Leu-Trp0.45% Leu Trp
enthält (erhalten durch Lösen des beschichteten Zuckers aus Beispiel 7), vermischt. In der Flasche wird diese Mischung mit der lOfachen Menge Wasser verdünnt, das bei 4 atü mit Kohlensäure gesättigt wurde. Die resultierende Limonade zeigt einen pH-Wert von 2,7 - 2,9.contains (obtained by dissolving the coated sugar from Example 7), mixed. Will be in the bottle this mixture was diluted with ten times the amount of water which was saturated with carbonic acid at 4 atmospheres. The resulting lemonade has a pH of 2.7-2.9.
Beispiel 3
Vergleich mit Chinin als BitterstoffExample 3
Comparison with quinine as a bitter substance
In einem Triangel- und Paartest wurde Chininhydrochloriddihydrat zu 103 mg/1 gegen das Diketopiperazin In a triangle and pair test, quinine hydrochloride dihydrate was found to 103 mg / 1 against the diketopiperazine
L-Leu-L-TrpL-Leu-L-Trp
zu 300 mg/1 in einer Limonadengrundlösung der Zusammensetzung (Angabe pro Liter):to 300 mg / 1 in a lemonade base solution of the composition (per liter):
0,5 g Zitronensäure0.5 g citric acid
0,5 g Weinsäure0.5 g of tartaric acid
0,15 g Milchsäure0.15 g of lactic acid
57,0 g Kristallzucker57.0 g granulated sugar
geprüft.checked.
Die Auswertung nach DIN 10 951 (Dreiecksprüfung) und DIN 10 954 (paarweise Unterschiedsprüfung) ergab bei einer Wahrscheinlichkeit von 95% keine signifikante Bevorzugung für einen der beiden Bitterstoffe.The evaluation according to DIN 10 951 (triangle test) and DIN 10 954 (pairwise difference test) resulted with a probability of 95% no significant preference for one of the two bitter substances.
In einem zusätzlichen orientierten Test mit 200 ppm (statt der im obigen Test verwendeten 300 ppm) wurde
keinerlei Unterschied mehr zu Chinin beobachtet.
Ein Hauptvorteil des erfindungsgemäß zu verwendenden Diketopiperazins ist seine geringe Toxizität. An
der Maus beträgt die LD50 für das Diketopiperazin
>4 g/kg, während sie für Chinin 0,5 g/kg ausmacht, so daß das Verhältnis größer als 8:1 ist. Obgleich das
Diketopiperazin etwa doppelt so hoch dosiert werden muß wie Chinin, bietet es immer noch eine beträchtlich
größere Sicherheit bei der Anwendung. Weiterhin zeigt Chinin erhebliche Nebenwirkungen. Beispielsweise
können am Menschen schon ab einer Dosierung von 0,033 g/kg Taubheit, Erblindung und Herzbesehwerden
hervorgerufen werden. Tierversuche mit dem Diketopiperazin geben - bei Dosen bis 4 g/kg - keine
Hinweise auf ähnliche Nebenwirkungen bei diesem Stoff.In an additional, oriented test with 200 ppm (instead of the 300 ppm used in the above test), no difference whatsoever to quinine was observed.
A main advantage of the diketopiperazine to be used according to the invention is its low toxicity. In the mouse, the LD 50 for the diketopiperazine is> 4 g / kg, while it is 0.5 g / kg for quinine, so that the ratio is greater than 8: 1. Although the diketopiperazine has to be dosed about twice as high as quinine, it still offers considerably greater safety in use. Quinine also shows considerable side effects. For example, a dose of 0.033 g / kg can cause deafness, blindness and heart problems in humans. Animal experiments with diketopiperazine - at doses of up to 4 g / kg - do not give any indications of similar side effects with this substance.
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE2840442A DE2840442C2 (en) | 1978-09-16 | 1978-09-16 | Use of the diketopiperazine L-Leu-L-Trp as a flavoring for beverages with a bitter taste |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE2840442A DE2840442C2 (en) | 1978-09-16 | 1978-09-16 | Use of the diketopiperazine L-Leu-L-Trp as a flavoring for beverages with a bitter taste |
Publications (2)
Publication Number | Publication Date |
---|---|
DE2840442A1 DE2840442A1 (en) | 1980-03-27 |
DE2840442C2 true DE2840442C2 (en) | 1982-02-11 |
Family
ID=6049673
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE2840442A Expired DE2840442C2 (en) | 1978-09-16 | 1978-09-16 | Use of the diketopiperazine L-Leu-L-Trp as a flavoring for beverages with a bitter taste |
Country Status (1)
Country | Link |
---|---|
DE (1) | DE2840442C2 (en) |
Cited By (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9192675B2 (en) | 2008-06-13 | 2015-11-24 | Mankind Corporation | Dry powder inhaler and system for drug delivery |
US9220687B2 (en) | 2008-12-29 | 2015-12-29 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
US9233159B2 (en) | 2011-10-24 | 2016-01-12 | Mannkind Corporation | Methods and compositions for treating pain |
US9241903B2 (en) | 2006-02-22 | 2016-01-26 | Mannkind Corporation | Method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent |
US9283193B2 (en) | 2005-09-14 | 2016-03-15 | Mannkind Corporation | Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents |
US9346766B2 (en) | 2004-08-20 | 2016-05-24 | Mannkind Corporation | Catalysis of diketopiperazine synthesis |
US9364436B2 (en) | 2011-06-17 | 2016-06-14 | Mannkind Corporation | High capacity diketopiperazine microparticles and methods |
US9364619B2 (en) | 2008-06-20 | 2016-06-14 | Mannkind Corporation | Interactive apparatus and method for real-time profiling of inhalation efforts |
US9630930B2 (en) | 2009-06-12 | 2017-04-25 | Mannkind Corporation | Diketopiperazine microparticles with defined specific surface areas |
US9662461B2 (en) | 2008-06-13 | 2017-05-30 | Mannkind Corporation | Dry powder drug delivery system and methods |
US9675674B2 (en) | 2004-08-23 | 2017-06-13 | Mannkind Corporation | Diketopiperazine salts for drug delivery and related methods |
US9700690B2 (en) | 2002-03-20 | 2017-07-11 | Mannkind Corporation | Inhalation apparatus |
US9706944B2 (en) | 2009-11-03 | 2017-07-18 | Mannkind Corporation | Apparatus and method for simulating inhalation efforts |
US9801925B2 (en) | 1999-06-29 | 2017-10-31 | Mannkind Corporation | Potentiation of glucose elimination |
US9802012B2 (en) | 2012-07-12 | 2017-10-31 | Mannkind Corporation | Dry powder drug delivery system and methods |
US9925144B2 (en) | 2013-07-18 | 2018-03-27 | Mannkind Corporation | Heat-stable dry powder pharmaceutical compositions and methods |
US9943571B2 (en) | 2008-08-11 | 2018-04-17 | Mannkind Corporation | Use of ultrarapid acting insulin |
US9983108B2 (en) | 2009-03-11 | 2018-05-29 | Mannkind Corporation | Apparatus, system and method for measuring resistance of an inhaler |
US10159644B2 (en) | 2012-10-26 | 2018-12-25 | Mannkind Corporation | Inhalable vaccine compositions and methods |
US10307464B2 (en) | 2014-03-28 | 2019-06-04 | Mannkind Corporation | Use of ultrarapid acting insulin |
US10342938B2 (en) | 2008-06-13 | 2019-07-09 | Mannkind Corporation | Dry powder drug delivery system |
US10421729B2 (en) | 2013-03-15 | 2019-09-24 | Mannkind Corporation | Microcrystalline diketopiperazine compositions and methods |
US10561806B2 (en) | 2014-10-02 | 2020-02-18 | Mannkind Corporation | Mouthpiece cover for an inhaler |
US10625034B2 (en) | 2011-04-01 | 2020-04-21 | Mannkind Corporation | Blister package for pharmaceutical cartridges |
US11446127B2 (en) | 2013-08-05 | 2022-09-20 | Mannkind Corporation | Insufflation apparatus and methods |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3115348A1 (en) * | 1981-04-15 | 1982-12-02 | Waldemar 8201 Thansau Leonhard | Beverage, containing fructose and vitamin C, for the accelerated reduction of the blood alcohol level, and process for the preparation of the beverage |
US6331318B1 (en) | 1994-09-30 | 2001-12-18 | Emisphere Technologies Inc. | Carbon-substituted diketopiperazine delivery systems |
WO2017168717A1 (en) * | 2016-03-31 | 2017-10-05 | サントリーホールディングス株式会社 | Packaged beverage |
-
1978
- 1978-09-16 DE DE2840442A patent/DE2840442C2/en not_active Expired
Cited By (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9801925B2 (en) | 1999-06-29 | 2017-10-31 | Mannkind Corporation | Potentiation of glucose elimination |
US9700690B2 (en) | 2002-03-20 | 2017-07-11 | Mannkind Corporation | Inhalation apparatus |
US9346766B2 (en) | 2004-08-20 | 2016-05-24 | Mannkind Corporation | Catalysis of diketopiperazine synthesis |
US9796688B2 (en) | 2004-08-20 | 2017-10-24 | Mannkind Corporation | Catalysis of diketopiperazine synthesis |
US10130685B2 (en) | 2004-08-23 | 2018-11-20 | Mannkind Corporation | Diketopiperazine salts for drug delivery and related methods |
US9675674B2 (en) | 2004-08-23 | 2017-06-13 | Mannkind Corporation | Diketopiperazine salts for drug delivery and related methods |
US9446001B2 (en) | 2005-09-14 | 2016-09-20 | Mannkind Corporation | Increasing drug affinity for crystalline microparticle surfaces |
US9283193B2 (en) | 2005-09-14 | 2016-03-15 | Mannkind Corporation | Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents |
US10143655B2 (en) | 2005-09-14 | 2018-12-04 | Mannkind Corporation | Method of drug formulation |
US9717689B2 (en) | 2005-09-14 | 2017-08-01 | Mannkind Corporation | Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents |
US10130581B2 (en) | 2006-02-22 | 2018-11-20 | Mannkind Corporation | Method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent |
US9241903B2 (en) | 2006-02-22 | 2016-01-26 | Mannkind Corporation | Method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent |
US9511198B2 (en) | 2008-06-13 | 2016-12-06 | Mannkind Corporation | Dry powder inhaler and system for drug delivery |
US10342938B2 (en) | 2008-06-13 | 2019-07-09 | Mannkind Corporation | Dry powder drug delivery system |
US9662461B2 (en) | 2008-06-13 | 2017-05-30 | Mannkind Corporation | Dry powder drug delivery system and methods |
US9339615B2 (en) | 2008-06-13 | 2016-05-17 | Mannkind Corporation | Dry powder inhaler and system for drug delivery |
US10751488B2 (en) | 2008-06-13 | 2020-08-25 | Mannkind Corporation | Dry powder inhaler and system for drug delivery |
US10201672B2 (en) | 2008-06-13 | 2019-02-12 | Mannkind Corporation | Dry powder inhaler and system for drug delivery |
US9192675B2 (en) | 2008-06-13 | 2015-11-24 | Mankind Corporation | Dry powder inhaler and system for drug delivery |
US9446133B2 (en) | 2008-06-13 | 2016-09-20 | Mannkind Corporation | Dry powder inhaler and system for drug delivery |
US10675421B2 (en) | 2008-06-20 | 2020-06-09 | Mannkind Corporation | Interactive apparatus and method for real-time profiling of inhalation efforts |
US9364619B2 (en) | 2008-06-20 | 2016-06-14 | Mannkind Corporation | Interactive apparatus and method for real-time profiling of inhalation efforts |
US9943571B2 (en) | 2008-08-11 | 2018-04-17 | Mannkind Corporation | Use of ultrarapid acting insulin |
US10172850B2 (en) | 2008-12-29 | 2019-01-08 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
US9220687B2 (en) | 2008-12-29 | 2015-12-29 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
US9655850B2 (en) | 2008-12-29 | 2017-05-23 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
US9983108B2 (en) | 2009-03-11 | 2018-05-29 | Mannkind Corporation | Apparatus, system and method for measuring resistance of an inhaler |
US9630930B2 (en) | 2009-06-12 | 2017-04-25 | Mannkind Corporation | Diketopiperazine microparticles with defined specific surface areas |
US9706944B2 (en) | 2009-11-03 | 2017-07-18 | Mannkind Corporation | Apparatus and method for simulating inhalation efforts |
US10625034B2 (en) | 2011-04-01 | 2020-04-21 | Mannkind Corporation | Blister package for pharmaceutical cartridges |
US10130709B2 (en) | 2011-06-17 | 2018-11-20 | Mannkind Corporation | High capacity diketopiperazine microparticles and methods |
US9364436B2 (en) | 2011-06-17 | 2016-06-14 | Mannkind Corporation | High capacity diketopiperazine microparticles and methods |
US10258664B2 (en) | 2011-10-24 | 2019-04-16 | Mannkind Corporation | Methods and compositions for treating pain |
US9233159B2 (en) | 2011-10-24 | 2016-01-12 | Mannkind Corporation | Methods and compositions for treating pain |
US9610351B2 (en) | 2011-10-24 | 2017-04-04 | Mannkind Corporation | Methods and compositions for treating pain |
US9802012B2 (en) | 2012-07-12 | 2017-10-31 | Mannkind Corporation | Dry powder drug delivery system and methods |
US10159644B2 (en) | 2012-10-26 | 2018-12-25 | Mannkind Corporation | Inhalable vaccine compositions and methods |
US10421729B2 (en) | 2013-03-15 | 2019-09-24 | Mannkind Corporation | Microcrystalline diketopiperazine compositions and methods |
US9925144B2 (en) | 2013-07-18 | 2018-03-27 | Mannkind Corporation | Heat-stable dry powder pharmaceutical compositions and methods |
US11446127B2 (en) | 2013-08-05 | 2022-09-20 | Mannkind Corporation | Insufflation apparatus and methods |
US10307464B2 (en) | 2014-03-28 | 2019-06-04 | Mannkind Corporation | Use of ultrarapid acting insulin |
US10561806B2 (en) | 2014-10-02 | 2020-02-18 | Mannkind Corporation | Mouthpiece cover for an inhaler |
Also Published As
Publication number | Publication date |
---|---|
DE2840442A1 (en) | 1980-03-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE2840442C2 (en) | Use of the diketopiperazine L-Leu-L-Trp as a flavoring for beverages with a bitter taste | |
DE4232465B4 (en) | Medicines or dietetic foods, their use and processes for their preparation | |
EP2194057B1 (en) | Stable crystalline calcium salt of 5-methyl-(6S)-tetrahydrofolic acid | |
DE3529529C2 (en) | ||
DE3500179C2 (en) | ||
DE2654184A1 (en) | Process for the production of bitter-flavored beverages | |
DE1467872A1 (en) | Process for the production of antibiotic substances | |
DE3310361A1 (en) | STABILIZED ANTHOCYANINE DYE, METHOD FOR THE PRODUCTION THEREOF AND THE USE THEREOF FOR COLORING FOODSTUFFS | |
DE68906765T2 (en) | COMPOSITION WITH AN EXTRACT OBTAINED BY EXTRACTION WITH A WATER-ORGANIC SOLVENT AND METHOD FOR THE PRODUCTION THEREOF. | |
EP0319984B1 (en) | Sweetener | |
DE2252665C2 (en) | ||
DE2734622C2 (en) | ||
EP0373103B1 (en) | Liquid oral formulation | |
DE60121459T2 (en) | CYANIDINE MIXTURE FOR THE TREATMENT OF THYROID CANCER | |
DE202008006491U1 (en) | Use of azo compounds for taste modulation of compositions containing at least one high intensity sweetener (HIS) | |
DE1769381A1 (en) | Red monoazo dyes and process for their preparation | |
DE1493618A1 (en) | Coumarin derivatives and a process for their preparation | |
DE3741961C1 (en) | Sweetener, process for the production thereof and use thereof | |
DE2609533B2 (en) | Process for the extraction of active substances, in particular of heteroside esters of caffeic acid, as well as medicaments containing these compounds | |
DE2162720A1 (en) | New alkoxynonanes and their use as aromatic substances | |
DE2015263C3 (en) | Process for the preparation of an orally administrable suspension of finely divided chloramphenicol palmitate | |
DE865142C (en) | Process for the preparation of rutin derivatives that are readily soluble in water | |
DE878876C (en) | Process for the production of pest repellants based on hexachlorocyclohexane which can be used without impairing the taste or odor of the harvested crop | |
RU2137826C1 (en) | Vodka "latsina" | |
DE2909707C2 (en) | Fominoben-theophylline complex and process for its preparation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
OAP | Request for examination filed | ||
OD | Request for examination | ||
D2 | Grant after examination | ||
8339 | Ceased/non-payment of the annual fee |